Viracta Therapeutics, Inc. (VIRX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Viracta Therapeutics, Inc. (VIRX)
Company Performance

Current Price

as of Oct 16, 2024

$0.22

P/E Ratio

N/A

Market Cap

$8.82M

Description

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Metrics

Overview

  • HQCardiff, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerVIRX
  • Price$0.2238+1.91%

Trading Information

  • Market Cap$8.82M
  • Float70.31%
  • Average Daily Volume (1m)159,308
  • Average Daily Volume (3m)638,886
  • EPS-$1.16

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$9.83M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$9.49M
  • EV$15.69M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/BN/A
Documents